Enter a word/phrase:


Transfer technologies
Pharmaceutical products and similar
Transfer technologies
Technologies for the synthesis of pharmaceutical substances, technology for extraction products from raw plant  materials...

read more

Mission, vision, values, history


The main mission of the National Institute For Chemical - Pharmaceutical Research and Development – ICCF Bucharest is to develop and suply new technologies, products and services for the pharmaceutical industry and therapeutic practice, this institute being the only research unit in the area of medicine obtainment in Romania capable of accomplishing the entire development cycle of a novel drug, beginning with the synthesis of the active pharmacological substance, and ending with the required documentation for market distribution.


Considering the existence of many ways to obtain medicines, the institute has developed through the years a large area of competences in:
- chemical synthesis
- microbial and plant extraction biotechnologies
- physical - chemical analysis
- modern pharmacological studies (of characterizing the drug’s action on a cellular level and on cell cultures, as an alternative to animal experiments)
- enzyme tests for clinical diagnosis
- high purity reagents
The research activity aims to enhance the quality level of the above-mentioned competences, which are essential in the development of new medicines and their technologies and, in the same time, cover many domains of research, by concentrating the resources in research directions in which, on one hand, the institute has experience and expertise, and, on the other hand, are modern and interesting in Romania, Europe and throughout world. Thus there can be found the niches in which the ICCF research may be acknowledged and integrated in the European space, bringing thus its contribution to the diminution of the technological gap exiting between Romania and other European countries and to the increase of the economic competitivity of our country.

Values: proffesional competence, creativity, inventivity, hardwork, honesty, responsability, team spirit and communication abilities, flexibility, research and performance ability


The Pharmaceutical Research Institute was founded in 01.01.1949 according to the decision of the Health and Social Protection Ministry, initially including Synthesis, analysis and pharmaceutical techniques laboratories and, later on, laboratories of plant extraction, biology, pharmacodynamics control and a pilot-station.
The period 1949-1953 was devoted mainly to maintaining and developing the technologies applicable in the pharmaceutical industry after the war, so that, in those difficult economical and political conditions, it could insure a list of Romanian medicines strictly required for maintaining the population health. On 01.02.1954 it became The Chemical-Pharmaceutical Research Institute, passing under the coordination of the Ministry of Chemical Industry. Between 1954 and 1970 there were developed and applied in industry 370 technologies of valuable medicines of almost all the therapeutic groups: semisynthetic penicillines, cardiovascular, antidiabetics, hormons, therapeutic enzymes. In 1967, the research area was enlarged towards high purity reagents and tests for clinical diagnosys.
In 1974, ICCF included new branches, namely the Research Centers from Iasi and Cluj, on the “Antibiotics” and, respectively, “Therapy” company platforms, as well as the research collective in Nivea-Brasov.
Until 1990, the research activity was developed under the following organizatorial structure: Department for Synthesis of Medicines for Human Use, Biosynthesis Departament (including a collective for research of medicines from animal tissue extracts), plant extract laboratory, Pharmaceutical Technology Laboratory, Laboratory for Synthesis of Medicines for Veterinary Use, Laboratory of Reagents, Laboratory of Physical-Chemical Analysis, Pharmacodynamics Laboratory for Medicines of Human and Veterinary Use, two units for irradiation researches – Radiochemistry and Radiobiology (in Bucharest), the Research Center of Cluj-Napoca (with a Department of Synthesis and a Laboratory for Cosmetics and Analysis), the Research Center for Antibiotics in Iasi (with a Departament for Biosynthesis of Medicines for Human Use and a Laboratory of Products for Veterinary Use) and a research collective form Nivea Brasov.
Between 1970 and 1980 there have been elaborated about 700 technologies, including synthesis and biosynthesis drugs, biostimulators, as well as medicines from plant and animal tissue extracts, more than 200 formulating technologies, around 300 technologies for reagents and cosmetics. These technologies represented about 90% of all those applied in the Romanian pharmaceutical industry.
In 1991, the research group of Brasov was moved to S.C. Nivea, and in 1998 the branches from Cluj and Iasi were reorganized as commercial companies, the former fusing with S.C“Terapia Cluj-Napoca”.
From 1996, the institute existed as The National Institute for Chemical-Pharmaceutical Research and Development (HG 1314/25.11.1996), under the coordination of the National Authority for Scientific Research. Through the course of its existence, the institute was the almost only supplier of technology for the entire pharmaceutical industry in Romania. After 1990, it has kept its core and unique competence in Romania to be able to completely develop a drug (from the synthesis of the active substance to the required documentation for the authorization). This competence was acknowledged by an external audit, during a PHARE project (1994 - 1995).
In the period 1990-2000, the necessity of insuring a degree of economical and financial independence as high as possible, led to the development of the production activity based on the own research products: 17 medicines, most of them unique in the Romanian industry, 30 tests for clinical diagnosys, more 60 plant extracts, about 100 high purity reagents and 20 active substances.
In spite of the difficult and challenging conditions of the transition period, the institute succeded in maintaining its acknowledged level of creative activity and, between 2003-2008, developed 79 techonologies and technological studies (from which 37 were technologies), 44 products and 295 methods, procedures and normatives.